It’s a new way to create “bi-paternal” mice that can survive to adulthood—but human applications are still a long way off.

"This type of gene editing should also allow for the treatment of diseases whose origin is not genetic or whose origin cannot ...

Mice with two fathers have been born—and have survived to adulthood—following a complex set of experiments by a team in China ...

Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

The human genome encodes potentially thousands of tiny proteins that were previously overlooked. The search is on to find out ...

Leerink Partnrs boosted their FY2024 earnings per share (EPS) estimates for CRISPR Therapeutics in a note issued to investors ...

This new tool, known as minimal, versatile genetic perturbation technology (mvGPT), combines the powers of gene editing, ...

Morgan Stanley lowered the firm’s price target on Crispr Therapeutics (CRSP) to $30 from $45 and keeps an Underweight rating on the shares. The ...

Justin Barbosa, GM and Vice President of TriLink Discovery, added “By integrating Molecular Assemblies technology into ...

RFK Jr.'s comments about the gene-editing technology raise a question about how he would regulate it as head of HHS.

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...